Epithelial to mesenchymal transition (EMT) contributes to tumor progression, cancer cell
invasion, and therapy resistance. EMT is regulated by transcription factors such as the …

Epithelial-to-mesenchymal transition (EMT) is a process in which epithelial cells lose their
junctions and polarity to gain a motile mesenchymal phenotype. EMT is essential during …

Tumor organoids maintain cell–cell interactions, heterogeneity, microenvironment, and drug
response of the sample they originate from. Thus, there is increasing interest in developing …

Malignant ovarian tumors bear the highest mortality rate among all gynecological cancers.
Both late tumor diagnosis and tolerance to available chemical therapy increase patient …

The epithelial-mesenchymal transition (EMT) has been implicated in conferring stem cell
properties and therapeutic resistance to cancer cells. Therefore, identification of drugs that …

Simple Summary Tumor heterogeneity promotes the development of drug resistance in
cancer. HDAC inhibitors modulate several processes that contribute to intra-tumoral …

Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have
been investigated for their therapeutic potential in various clinical disorders, including …

The majority of women diagnosed with epithelial ovarian cancer eventually develop
recurrence, which rapidly evolves into chemoresistant disease. Persistence of ovarian …

We present Beyondcell, a computational methodology for identifying tumour cell
subpopulations with distinct drug responses in single-cell RNA-seq data and proposing …

Carcinomas are phenotypically arrayed along an epithelial–mesenchymal transition (EMT)
spectrum, a developmental program currently exploited to understand the acquisition of drug …